|
|
Blood, 1 January 2004, Vol. 103, No. 1, pp. 242-251.
Prepublished online as a Blood First Edition Paper on September 11, 2003; DOI 10.1182/blood-2003-04-1048.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Interleukin-6dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 familyindependent survival pathway closely associated with Stat3 activation
Katja Brocke-Heidrich,
Antje K. Kretzschmar,
Gabriele Pfeifer,
Christian Henze,
Dennis Löffler,
Dirk Koczan,
Hans-Jürgen Thiesen,
Renate Burger,
Martin Gramatzki, and
Friedemann Horn
From the Institute of Clinical Immunology and Transfusion Medicine, University of Leipzig, Leipzig, Germany; Department of Immunology, University of Rostock, Faculty of Medicine, Rostock, Germany; Division of Hematology/Oncology, Department of Medicine III, University of Erlangen-Nürnberg, Erlangen, Germany.
Interleukin 6 (IL-6) is a growth and survival factor for multiple myeloma cells. As we report here, the IL-6dependent human myeloma cell line INA-6 responds with a remarkably rapid and complete apoptosis to cytokine withdrawal. Among the antiapoptotic members of the B-cell lymphoma-2 (Bcl-2) family of apoptosis regulators, only myeloid cell factor-1 (Mcl-1) was slightly induced by IL-6. Overexpression studies demonstrated, however, that IL-6 does not exert its survival effect primarily through this pathway. The IL-6 signal transduction pathways required for survival and the target genes controlled by them were analyzed by using mutated receptor chimeras. The activation of signal transducer and activator of transcription 3 (Stat3) turned out to be obligatory for the survival of INA-6 cells. The same held true for survival and growth of XG-1 myeloma cells. Gene expression profiling of INA-6 cells by using oligonucleotide microarrays revealed many novel IL-6 target genes, among them several genes coding for transcriptional regulators involved in B-lymphocyte differentiation as well as for growth factors and receptors potentially implicated in autocrine or paracrine growth control. Regulation of most IL-6 target genes required the activation of Stat3, underscoring its central role for IL-6 signal transduction. Taken together, our data provide evidence for the existence of an as yet unknown Stat3-dependent survival pathway in myeloma cells.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. H. Shain, D. N. Yarde, M. B. Meads, M. Huang, R. Jove, L. A. Hazlehurst, and W. S. Dalton
{beta}1 Integrin Adhesion Enhances IL-6-Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation
Cancer Res.,
February 1, 2009;
69(3):
1009 - 1015.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Burger, S. Le Gouill, Y.-T. Tai, R. Shringarpure, P. Tassone, P. Neri, K. Podar, L. Catley, T. Hideshima, D. Chauhan, et al.
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo
Mol. Cancer Ther.,
January 1, 2009;
8(1):
26 - 35.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-W. Cheng, H. Lee, M.-Y. Shiau, T.-C. Wu, T.-T. Huang, and Y.-H. Chang
Human Papillomavirus Type 16/18 Up-Regulates the Expression of Interleukin-6 and Antiapoptotic Mcl-1 in Non-Small Cell Lung Cancer
Clin. Cancer Res.,
August 1, 2008;
14(15):
4705 - 4712.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U.-M. Fagerli, R. U. Holt, T. Holien, T. K. Vaatsveen, F. Zhan, K. W. Egeberg, B. Barlogie, A. Waage, H. Aarset, H. Y. Dai, et al.
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells
Blood,
January 15, 2008;
111(2):
806 - 815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein
Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications
Clin. Cancer Res.,
December 15, 2007;
13(24):
7289 - 7295.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Hurt and W. L. Farrar
The STATus of miR-21 in apoptosis
Blood,
August 15, 2007;
110(4):
1086 - 1087.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Loffler, K. Brocke-Heidrich, G. Pfeifer, C. Stocsits, J. Hackermuller, A. K. Kretzschmar, R. Burger, M. Gramatzki, C. Blumert, K. Bauer, et al.
Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer
Blood,
August 15, 2007;
110(4):
1330 - 1333.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Muto, M. Hori, Y. Sasaki, A. Saitoh, I. Yasuda, T. Maekawa, T. Uchida, K. Asakura, T. Nakazato, T. Kaneda, et al.
Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor
Mol. Cancer Ther.,
March 1, 2007;
6(3):
987 - 994.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Burger, H. Czekalla, K. Richter, T. Ahrens, A. Guenther, and M. Gramatzki
Green Tea Polyphenol (-)-Epigallocatechin Gallate Inhibits IL-6 Mediated Signalling Pathways in Human Myeloma Cells.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
5049 - 5049.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Maggio, J. M. Guralnik, D. L. Longo, and L. Ferrucci
Interleukin-6 in aging and chronic disease: a magnificent pathway.
J. Gerontol. A Biol. Sci. Med. Sci.,
June 1, 2006;
61(6):
575 - 584.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Cortez, C. A. Lyman, S. Kottilil, H. S. Kim, E. Roilides, J. Yang, B. Fullmer, R. Lempicki, and T. J. Walsh
Functional Genomics of Innate Host Defense Molecules in Normal Human Monocytes in Response to Aspergillus fumigatus
Infect. Immun.,
April 1, 2006;
74(4):
2353 - 2365.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Chen, S. Tsui, and T. J. Smith
IL-1{beta} Induces IL-6 Expression in Human Orbital Fibroblasts: Identification of an Anatomic-Site Specific Phenotypic Attribute Relevant to Thyroid-Associated Ophthalmopathy
J. Immunol.,
July 15, 2005;
175(2):
1310 - 1319.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. V. Alvarez, P. G. Febbo, S. Ramaswamy, M. Loda, A. Richardson, and D. A. Frank
Identification of a Genetic Signature of Activated Signal Transducer and Activator of Transcription 3 in Human Tumors
Cancer Res.,
June 15, 2005;
65(12):
5054 - 5062.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Chatterjee, T. Stuhmer, P. Herrmann, K. Bommert, B. Dorken, and R. C. Bargou
Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells
Blood,
December 1, 2004;
104(12):
3712 - 3721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. J. Vanasse, R. K. Winn, S. Rodov, A. W. Zieske, J. T. Li, J. C. Tupper, J. Tang, E. W. Raines, M. A. Peters, K. Y. Yeung, et al.
Bcl-2 Overexpression Leads to Increases in Suppressor of Cytokine Signaling-3 Expression in B Cells and De novo Follicular Lymphoma
Mol. Cancer Res.,
November 1, 2004;
2(11):
620 - 631.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|